TY - JOUR
T1 - Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy
T2 - Safety and Efficacy Results of a Phase II-A Randomized Trial
AU - Butler, Javed
AU - Epstein, Stephen E.
AU - Greene, Stephen J.
AU - Quyyumi, Arshed A.
AU - Sikora, Sergey
AU - Kim, Raymond J.
AU - Anderson, Allen S.
AU - Wilcox, Jane E.
AU - Tankovich, Nikolai I.
AU - Lipinski, Michael J.
AU - Ko, Yi An
AU - Margulies, Kenneth B.
AU - Cole, Robert T.
AU - Skopicki, Hal A.
AU - Gheorghiade, Mihai
N1 - Publisher Copyright:
© 2016 American Heart Association, Inc.
PY - 2017/1/20
Y1 - 2017/1/20
N2 - Rationale: Potential benefits of mesenchymal stem cell (MSC) therapy in heart failure may be related to paracrine properties and systemic effects, including anti-inflammatory activities. If this hypothesis is valid, intravenous administration of MSCs should improve outcomes in heart failure, an entity in which excessive chronic inflammation may play a pivotal role. Objective: To assess the safety and preliminary efficacy of intravenously administered ischemia-tolerant MSCs (itMSCs) in patients with nonischemic cardiomyopathy. Methods and Results: This was a single-blind, placebo-controlled, crossover, randomized phase II-a trial of nonischemic cardiomyopathy patients with left ventricular ejection fraction ≤40% and absent hyperenhancement on cardiac magnetic resonance imaging. Patients were randomized to intravenously administered itMSCs (1.5×10 6 cells/kg) or placebo; at 90 days, each group received the alternative treatment. Overall, 22 patients were randomized to itMSC (n=10) and placebo (n=12) at baseline. After crossover, data were available for 22 itMSC patients. No major differences in death, hospitalization, or serious adverse events were noted between the 2 treatments. Change from baseline in left ventricular ejection fraction and ventricular volumes was not significantly different between therapies. Compared with placebo, itMSC therapy increased 6-minute walk distance (+36.47 m, 95% confidence interval 5.98-66.97; P=0.02) and improved Kansas City Cardiomyopathy clinical summary (+5.22, 95% confidence interval 0.70-9.74; P=0.02) and functional status scores (+5.65, 95% confidence interval -0.11 to 11.41; P=0.06). The data demonstrated MSC-induced immunomodulatory effects, the magnitude of which correlated with improvement in left ventricular ejection fraction. Conclusions: In this pilot study of patients with nonischemic cardiomyopathy, itMSC therapy was safe, caused immunomodulatory effects, and was associated with improvements in health status and functional capacity.
AB - Rationale: Potential benefits of mesenchymal stem cell (MSC) therapy in heart failure may be related to paracrine properties and systemic effects, including anti-inflammatory activities. If this hypothesis is valid, intravenous administration of MSCs should improve outcomes in heart failure, an entity in which excessive chronic inflammation may play a pivotal role. Objective: To assess the safety and preliminary efficacy of intravenously administered ischemia-tolerant MSCs (itMSCs) in patients with nonischemic cardiomyopathy. Methods and Results: This was a single-blind, placebo-controlled, crossover, randomized phase II-a trial of nonischemic cardiomyopathy patients with left ventricular ejection fraction ≤40% and absent hyperenhancement on cardiac magnetic resonance imaging. Patients were randomized to intravenously administered itMSCs (1.5×10 6 cells/kg) or placebo; at 90 days, each group received the alternative treatment. Overall, 22 patients were randomized to itMSC (n=10) and placebo (n=12) at baseline. After crossover, data were available for 22 itMSC patients. No major differences in death, hospitalization, or serious adverse events were noted between the 2 treatments. Change from baseline in left ventricular ejection fraction and ventricular volumes was not significantly different between therapies. Compared with placebo, itMSC therapy increased 6-minute walk distance (+36.47 m, 95% confidence interval 5.98-66.97; P=0.02) and improved Kansas City Cardiomyopathy clinical summary (+5.22, 95% confidence interval 0.70-9.74; P=0.02) and functional status scores (+5.65, 95% confidence interval -0.11 to 11.41; P=0.06). The data demonstrated MSC-induced immunomodulatory effects, the magnitude of which correlated with improvement in left ventricular ejection fraction. Conclusions: In this pilot study of patients with nonischemic cardiomyopathy, itMSC therapy was safe, caused immunomodulatory effects, and was associated with improvements in health status and functional capacity.
KW - cardiomyopathy
KW - clinical trial
KW - heart failure
KW - noni
KW - schemic
KW - stem cells
KW - viable myocardium
UR - http://www.scopus.com/inward/record.url?scp=85000613472&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85000613472&partnerID=8YFLogxK
U2 - 10.1161/CIRCRESAHA.116.309717
DO - 10.1161/CIRCRESAHA.116.309717
M3 - Article
C2 - 27856497
AN - SCOPUS:85000613472
SN - 0009-7330
VL - 120
SP - 332
EP - 340
JO - Circulation research
JF - Circulation research
IS - 2
ER -